Evidence map›Paper›PMID 25304766›Full record

Trial reportCephalalgia : an international journal of headache2015

The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results.

Aubrey Manack Adams, Daniel Serrano, Dawn C Buse, Michael L Reed, Valerie Marske, Kristina M Fanning, Richard B Lipton

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cephalalgia : an international journal of headache, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. The Use of Botulinum Toxin in the Management of Headache Disorders.Handbook of experimental pharmacology · 2021
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aubrey Manack AdamsAllergan Inc., Irvine, CA, USA adams_aubrey@allergan.com.
Daniel SerranoVedanta Research, Chapel Hill, NC, USA Endpoint Outcomes, Boston, MA, USA The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
Dawn C BuseThe Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA Montefiore Headache Center, Bronx, NY, USA.
Michael L ReedVedanta Research, Chapel Hill, NC, USA.
Valerie MarskeVedanta Research, Chapel Hill, NC, USA.
Kristina M FanningVedanta Research, Chapel Hill, NC, USA.
Richard B LiptonThe Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA Montefiore Headache Center, Bronx, NY, USA.

Funding

Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Charles B Hall · 1985 to 2026
$73.9M
PREDICTORS OF COGNITIVE DECLINE IN NORMAL AGINGR01AG012101 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DE LEON, MONY J., RUSINEK, HENRY · 1993 to 2015
$6.7M
Biomarkers in Early Alzheimer's Disease (AD).R01AG022374 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DE LEON, MONY J., RUSINEK, HENRY · 2004 to 2015
$5.2M
TWO PRECLINICAL LATENT SCORES TO PREDICT OCCURRENCE OF DATR01AG034119 · NIA · WASHINGTON UNIVERSITY · PI XIONG, CHENGJIE · 2010 to 2014
$1.6M
Latent Mobility Abnormalities And FrailtyR01AG025119 · NIA · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI VERGHESE, JOE · 2005 to 2009
$1.5M
Gender and Hormonal Differences in Parkinson's DiseaseK23NS047256 · NINDS · BETH ISRAEL MEDICAL CTR (NEW YORK) · PI SAUNDERS-PULLMAN, RACHEL · 2004 to 2008
$869k
Predictors of Gait and Falls in Aging: Linking Cognitive Control to GenesK23AG030857 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI HOLTZER, ROEE · 2007 to 2011
$841k
NIA NIH HHS K23AG030857NIA NIH HHS P01 AG03949NIA NIH HHS R01AG022374-06A2NIA NIH HHS R01AG025119NIA NIH HHS R01AG034119NIA NIH HHS R01AG12101NINDS NIH HHS K23NS05140901A1NINDS NIH HHS K23NS47256
6 · The paper itself

Abstract

backgroundLongitudinal migraine studies have rarely assessed headache frequency and disability variation over a year.

methodsThe Chronic Migraine Epidemiology and Outcomes (CaMEO) Study is a cross-sectional and longitudinal Internet study designed to characterize the course of episodic migraine (EM) and chronic migraine (CM). Participants were recruited from a Web-panel using quota sampling in an attempt to obtain a sample demographically similar to the US population. Participants who passed the screener were assessed every three months with the Core (baseline, six, and 12 months) and Snapshot (months three and nine) modules, which assessed headache frequency, headache-related disability, treatments, and treatment satisfaction. The Core also assessed resource use, health-related quality of life, and other features. One-time cross-sectional modules measured family burden, barriers to medical care, and comorbidities/endophenotypes.

resultsOf 489,537 invitees, we obtained 58,418 (11.9%) usable returns including 16,789 individuals who met ICHD-3 beta migraine criteria (EM (<15 headache days/mo): n = 15,313 (91.2%); CM (≥ 15 headache days/mo): n = 1476 (8.8%)). At baseline, all qualified respondents (n = 16,789) completed the Screener, Core, and Barriers to Care modules. Subsequent modules showed some attrition (Comorbidities/Endophenotypes, n = 12,810; Family Burden (Proband), n = 13,064; Family Burden (Partner), n = 4022; Family Burden (Child), n = 2140; Snapshot (three months), n = 9741; Core (six months), n = 7517; Snapshot (nine months), n = 6362; Core (12 months), n = 5915). A total of 3513 respondents (21.0%) completed all modules, and 3626 (EM: n = 3303 (21.6%); CM: n = 323 (21.9%)) completed all longitudinal assessments.

conclusionsThe CaMEO Study provides cross-sectional and longitudinal data that will contribute to our understanding of the course of migraine over one year and quantify variations in headache frequency, headache-related disability, comorbidities, treatments, and familial impact.

Indexed as

Sickness Impact ProfileAdultChronic DiseaseCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedMigraine DisordersTreatment Outcomechronic migraineepidemiologyepisodic migraineheadacheMigraine disorders

Identifiers

PMID25304766
PMCPMC4430584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.